MRUS - Merus N.V.
NASDAQ
->
Healthcare
->
Biotechnology
Utrecht,
Netherlands
Type: Equity
MRUS price evolution
MRUS
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $3.98 | $4.61 | $3.81 | $5.61 |
| Inventory | ||||
| Total current assets | $368.81 | $404.83 | $283.13 | $258.16 |
| Long term investments | ||||
| Property, plant & equipment | $23.5 | $23.5 | $25 | $25.71 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $455.49 | $492.19 | $363.62 | $338.52 |
| Current liabilities | ||||
| Accounts payable | $4.6 | $3.84 | $7.6 | $4.99 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $69.09 | $64.32 | $65.85 | $75.09 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $99.15 | $98.8 | $106.22 | $121 |
| Shareholders' equity | ||||
| Retained earnings | -$753.06 | -$692.91 | -$669.9 | -$637.86 |
| Other shareholder equity | -$22.53 | -$37.43 | -$26.71 | -$26.21 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $241.44 | $163.08 | ||
| Short term investments | $168.99 | $44.67 | ||
| Net receivables | $3.98 | $4.7 | $6.31 | $1.75 |
| Inventory | ||||
| Total current assets | $368.81 | $306.44 | $424.18 | $217.99 |
| Long term investments | $20.3 | |||
| Property, plant & equipment | $23.5 | $24.84 | $7.28 | $8.02 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $13.22 | |||
| Total investments | ||||
| Total assets | $455.49 | $376.54 | $456.6 | $231.22 |
| Current liabilities | ||||
| Accounts payable | $4.6 | $9.83 | $13.24 | $3.13 |
| Deferred revenue | $20.18 | |||
| Short long term debt | ||||
| Total current liabilities | $69.09 | $78.93 | $71.9 | $46.75 |
| Long term debt | ||||
| Total noncurrent liabilities | $82.21 | |||
| Total debt | ||||
| Total liabilities | $99.15 | $129.49 | $140.4 | $128.95 |
| Shareholders' equity | ||||
| Retained earnings | -$753.06 | -$598.12 | -$466.93 | -$400.11 |
| Other shareholder equity | -$22.53 | -$30.45 | -$9.22 | $9.07 |
| Total shareholder equity | $316.2 | $102.26 | ||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8.94 | $11.03 | $10.48 | $13.5 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $56.48 | $49.4 | $44.36 | $50.25 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $1.04 | $1.12 | $1.49 | -$0.46 |
| Interest expense | -$11.57 | $16.47 | $3.35 | -$3.45 |
| Net income | ||||
| Net income | -$60.15 | -$23.01 | -$32.03 | -$39.74 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $43.95 | $41.59 | $29.94 | |
| Cost of revenue | $70.04 | |||
| Gross Profit | -$40.1 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $35.78 | |||
| Total operating expenses | $200.49 | $201.62 | $105.82 | |
| Operating income | -$75.88 | |||
| Income from continuing operations | ||||
| EBIT | -$75.88 | |||
| Income tax expense | $3.19 | $0.96 | $0.5 | |
| Interest expense | $4.8 | $28.74 | ||
| Net income | ||||
| Net income | -$154.94 | -$131.19 | -$85.51 | |
| Income (for common shares) | -$85.51 | |||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$27.02 | -$24.9 | -$32.92 | -$8.41 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $230.09 | $228.59 | $66.18 | $0.22 |
| Effect of exchange rate | -$4.29 | -$3.65 | -$1.51 | -$0.17 |
| Change in cash and equivalents | $56.58 | $94.18 | -$46.58 | -$45.1 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$66.82 | -$85.51 | ||
| Operating activities | ||||
| Depreciation | $1.44 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$79.9 | |||
| Investing activities | ||||
| Capital expenditures | -$1.29 | |||
| Investments | -$0.2 | |||
| Total cash flows from investing | -$27.02 | $2.8 | -$1.49 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $230.09 | $58.74 | $39.52 | |
| Effect of exchange rate | -$4.28 | -$4.95 | $7.34 | |
| Change in cash and equivalents | $56.58 | -$93.31 | -$34.53 | |
News
Fundamentals
| Market cap | $2.57B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 57.83M |
| Revenue | $43.95M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$154.94M |
| Revenue Q/Q | -16.19% |
| Revenue Y/Y | N/A |
| P/E ratio | -16.62 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 58.58 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.68 |
|---|---|
| ROA | -37.56% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.34 |
| Quick ratio | N/A |